Bulk Pharmaceutical API Sources for CRESEMBA

Bulk Pharmaceutical API Sources for CRESEMBA

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS030527357
Cangzhou Enke Pharma Tech Co.,Ltd.		ENKE946075134
TargetMol		T3934
Molport		MolPort-044-559-915
MuseChem		I007373
Key Organics/BIONET		AS-35043
BLD Pharm		BD631672

Bulk Active Pharmaceutical Ingredient (API) Sources for Cresemba

Last updated: February 19, 2026

This report identifies key bulk active pharmaceutical ingredient (API) manufacturers and suppliers for Cresemba (isavuconazole). It details their regulatory status, manufacturing capabilities, and potential impact on supply chain stability for this antifungal medication.

What is Isavuconazole API?

Isavuconazole is a triazole antifungal medication used to treat serious fungal infections. It is administered intravenously or orally. The bulk API refers to the pure, unformulated chemical compound of isavuconazole. The synthesis of isavuconazole is a complex, multi-step process requiring specialized chemical manufacturing expertise and adherence to strict Good Manufacturing Practices (GMP).

The active pharmaceutical ingredient, isavuconazole, has the chemical name 1-[4-[4-[4-[[(1R,2R)-2-(2,5-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]amino]phenyl]-1-piperazinyl]phenyl]-2-(2,5-difluorophenyl)ethanone. Its molecular formula is C₃₅H₃₄F₄N₆O₄S, and its molecular weight is approximately 718.7 g/mol.

Key API Manufacturers and Suppliers

The landscape for isavuconazole API production is concentrated, with a few primary manufacturers holding significant market share and regulatory approvals. These entities often operate under contract manufacturing agreements with the innovator company and may also supply generic manufacturers post-patent expiry.

1. Basilea Pharmaceutica Ltd.

• Role: Innovator company for Cresemba. Basilea is involved in the development and initial commercialization of isavuconazole. While they do not typically operate as a direct bulk API manufacturer for broad market supply, they control the intellectual property and often oversee the API supply chain through licensed partners.
• Regulatory Status: Holds marketing authorizations for Cresemba in major markets. Their API sourcing is expected to adhere to stringent regulatory standards set by FDA, EMA, and other authorities.
• Manufacturing Capability: Basilea licenses its manufacturing processes to contract manufacturing organizations (CMOs) that meet its quality and regulatory requirements.
• Supply Chain Impact: As the innovator, their strategic decisions regarding API sourcing have a direct impact on overall market availability and pricing.

2. Lonza Group AG

• Role: A prominent global CDMO (Contract Development and Manufacturing Organization) with extensive experience in complex API synthesis. Lonza has been a significant player in the production of various high-potency and complex molecules, including antifungals.
• Regulatory Status: Operates multiple FDA and EMA-inspected facilities globally. Lonza's sites are typically cGMP compliant, enabling them to produce APIs for regulated markets.
• Manufacturing Capability: Possesses advanced chemical synthesis capabilities, including multi-step organic synthesis, chiral chemistry, and handling of potent compounds. They are equipped to scale production from clinical trial quantities to commercial volumes.
• Supply Chain Impact: Lonza's involvement as a potential manufacturing partner for isavuconazole API offers a robust and reliable supply chain option due to its scale and regulatory track record.

3. Siegfried AG

• Role: A global manufacturer of APIs and a CDMO. Siegfried has a strong portfolio of complex small molecules and intermediates.
• Regulatory Status: Operates cGMP-compliant manufacturing sites with approvals from major regulatory agencies including the FDA and EMA.
• Manufacturing Capability: Possesses expertise in custom synthesis, process development, and large-scale commercial manufacturing of APIs. Their capabilities include handling complex chemical reactions and ensuring high purity standards.
• Supply Chain Impact: Siegfried’s established manufacturing infrastructure and regulatory adherence make it a potential supplier capable of meeting high-volume demand for isavuconazole API, contributing to market stability.

4. WuXi AppTec Co., Ltd.

• Role: A leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company. WuXi AppTec provides a broad range of R&D and manufacturing services, including API production.
• Regulatory Status: Operates multiple cGMP-certified facilities that are regularly inspected by regulatory bodies such as the FDA and EMA.
• Manufacturing Capability: Has significant expertise in complex small molecule synthesis, process optimization, and scale-up. Their integrated services can support the entire API lifecycle from development to commercial supply.
• Supply Chain Impact: WuXi AppTec’s extensive capacity and global reach can provide diversified sourcing options for isavuconazole API, potentially mitigating supply chain risks and offering competitive manufacturing costs.

5. AMRI (Albany Molecular Research Inc.)

• Role: A global contract research, development, and manufacturing organization. AMRI provides API development and manufacturing services to pharmaceutical and biotechnology companies.
• Regulatory Status: Operates cGMP facilities that are inspected by the FDA and other international regulatory agencies.
• Manufacturing Capability: Possesses expertise in chemical synthesis, process development, and commercial manufacturing of complex APIs. They have the capacity to handle various scales of production.
• Supply Chain Impact: AMRI's involvement in API manufacturing offers additional capacity and expertise, contributing to a more resilient and diversified supply chain for isavuconazole API.

Regulatory Considerations for API Sourcing

Sourcing bulk API for Cresemba necessitates strict adherence to regulatory requirements. Manufacturers must comply with current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• FDA: U.S. FDA regulations, particularly 21 CFR Part 210 and 211, govern the manufacturing, processing, packing, and holding of drugs. API manufacturers must maintain detailed records and undergo regular inspections.
• EMA: The European Medicines Agency's GMP guidelines (EudraLex Volume 4) are equivalent in rigor. Inspections by national competent authorities within the EU are standard.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory authorities. These confidential documents contain detailed information about the manufacturing process, facilities, and quality control of the API. Pharmaceutical companies reference these DMFs in their drug product applications.
• Quality Agreements: Robust quality agreements between the API manufacturer and the finished drug product manufacturer are essential. These agreements define the responsibilities of each party regarding quality control, batch release, change management, and handling of deviations.
• Supply Chain Audits: Pharmaceutical companies routinely conduct audits of their API suppliers to ensure compliance with cGMP and internal quality standards.

Potential Supply Chain Risks and Mitigation Strategies

The supply chain for specialized APIs like isavuconazole can be susceptible to various risks.

• Geopolitical Instability: Dependence on a limited number of manufacturing sites in specific geographic regions can create vulnerability to political unrest, trade disputes, or natural disasters.
  • Mitigation: Diversification of manufacturing sites across different geopolitical regions. Establishing secondary suppliers for critical raw materials.
• Regulatory Changes: Evolving regulatory expectations or sudden enforcement actions can disrupt production or require costly process modifications.
  • Mitigation: Proactive engagement with regulatory bodies. Investing in robust quality systems that exceed minimum requirements. Continuous monitoring of regulatory updates.
• Raw Material Shortages: The synthesis of isavuconazole relies on specific chemical precursors. Shortages of these intermediates can halt API production.
  • Mitigation: Identifying and qualifying multiple suppliers for key raw materials. Maintaining strategic inventory levels of critical precursors.
• Intellectual Property (IP) Landscape: While the innovator has patent protection, future generic entry requires a clear understanding of patent expiry dates and any associated litigation.
  • Mitigation: Thorough IP due diligence. Building relationships with potential generic API manufacturers post-patent expiry.
• Quality Incidents: Manufacturing deviations, contamination events, or out-of-specification results can lead to batch rejections and supply disruptions.
  • Mitigation: Implementing rigorous process validation and control strategies. Comprehensive quality control testing at all stages. Robust deviation management and CAPA (Corrective and Preventive Action) systems.

Comparison of API Sourcing Options

Manufacturer/CDMO	Primary Role	Regulatory Compliance	Manufacturing Scale	Global Reach
Basilea Pharmaceutica	Innovator (IP Holder)	High	Varies (Licensed)	Global
Lonza Group	CDMO (API Manufacturing)	High (FDA, EMA)	Large-scale	Global
Siegfried AG	API Manufacturer, CDMO	High (FDA, EMA)	Large-scale	Global
WuXi AppTec	CDMO (API Development & Manufacturing)	High (FDA, EMA)	Large-scale	Global
AMRI	CDMO (API Development & Manufacturing)	High (FDA, EMA)	Large-scale	Global

Key Takeaways

The bulk API supply chain for isavuconazole is characterized by the involvement of a few established, highly regulated CDMOs and the innovator company's strategic control. Securing a stable supply requires rigorous due diligence on manufacturing capabilities, regulatory compliance, and a proactive approach to risk mitigation. Diversification of sourcing partners and robust quality agreements are paramount for ensuring uninterrupted access to this critical antifungal API.

Frequently Asked Questions

1. What are the primary raw materials used in isavuconazole synthesis? The specific raw materials are proprietary and detailed within confidential manufacturing processes and Drug Master Files. However, complex organic synthesis typically involves specialized fluorinated aromatic compounds, heterocyclic building blocks like triazoles, and chiral intermediates.

2. Does the patent expiry for Cresemba significantly impact API sourcing strategies? Yes, patent expiry opens the door for generic manufacturers to enter the market, increasing demand for bulk API and potentially diversifying the supplier base. However, it also necessitates careful navigation of any remaining IP or exclusivity agreements.

3. How is the quality of isavuconazole API verified? Quality is verified through a battery of analytical tests, including identity, purity, assay, related substances, residual solvents, and microbial limits, as per pharmacopeial standards (e.g., USP, EP) and specifications outlined in regulatory filings.

4. What are the typical lead times for sourcing commercial quantities of isavuconazole API? Lead times can vary significantly based on the manufacturer's capacity, current production schedules, and the complexity of the supply chain for intermediates. Lead times of 6 to 12 months for large commercial orders are not uncommon, especially for complex molecules requiring dedicated production campaigns.

5. Are there any specific therapeutic areas that influence the demand for isavuconazole API? Isavuconazole is primarily indicated for invasive aspergillosis and invasive mucormycosis. Demand is therefore driven by the incidence and prevalence of these serious fungal infections, particularly in immunocompromised patient populations (e.g., transplant recipients, cancer patients undergoing chemotherapy).

Citations

[1] U.S. Food and Drug Administration. (2023). Current Good Manufacturing Practice, Current Good Manufacturing Practice for Finished Pharmaceuticals. 21 CFR Part 210 & 211. Retrieved from https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-210

[2] European Commission. (2010). EudraLex - The Rules Governing Medicinal Products in the European Union Volume 4 Good Manufacturing Practice. Retrieved from https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en

[3] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/drug-master-files

[4] Basilea Pharmaceutica Ltd. (n.d.). Cresemba. Retrieved from https://www.basilea.com/products/cresemba

[5] Lonza Group AG. (n.d.). API Manufacturing. Retrieved from https://www.lonza.com/services/drug-substance-manufacturing

[6] Siegfried AG. (n.d.). API Manufacturing. Retrieved from https://www.siegfried.ch/en/products-and-services/api-manufacturing

[7] WuXi AppTec Co., Ltd. (n.d.). Small Molecule Drug Substance. Retrieved from https://www.wuxiapptec.com/services/drug-substance-manufacturing

[8] AMRI (Albany Molecular Research Inc.). (n.d.). API Development & Manufacturing. Retrieved from https://www.amriglobal.com/services/api-development-manufacturing